Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date
This article was originally published in PharmAsia News
Executive Summary
Arena Pharmaceuticals has won an early race against Vivus and Orexigen Therapeutics in finding a commercialization partner for its obesity drug candidate lorcaserin. The three companies are vying to bring the first new obesity drug to the market in over a decade, with U.S. FDA action dates for the three candidates scheduled between October and January
You may also be interested in...
Takeda Bulks Up In Obesity With Orexigen Deal
Takeda, already a strong player in diabetes, is looking to be a leader in obesity as well. Obesity is a risky area of drug development, given regulatory concerns about safety and efficacy, not to mention payer resistance. But despite those roadblocks, Takeda added to its substantial obesity pipeline through a deal with Orexigen Therapeutics, announced Sept. 2
Takeda Bulks Up In Obesity With Orexigen Deal
Takeda, already a strong player in diabetes, is looking to be a leader in obesity as well. Obesity is a risky area of drug development, given regulatory concerns about safety and efficacy, not to mention payer resistance. But despite those roadblocks, Takeda added to its substantial obesity pipeline through a deal with Orexigen Therapeutics, announced Sept. 2
Arena Optimistic About Lorcaserin But Analysts More Reserved
Arena Pharmaceuticals argues it has the necessary safety data to convince an FDA advisory committee to recommend approval of its key drug, a weight loss treatment.